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[1_TD$DIFF]Academic Urology Unit, University of Sheffield, Sheffield, UKWe would like to congratulate Ueno and colleagues [1] on
their paper on diagnostic accuracy and interobserver
agreement for the new Vesical Imaging-Reporting and Data
System (VI-RADS) [2] for muscle-invasive bladder cancer
(MIBC) in this issue of European Urology. Their report on
74 patients who underwent multiparametric magnetic
resonance imaging (mpMRI) before transurethral resection
of bladder tumor (TURBT) raises great interest in the RADS
(Reporting and Data Systems) era. They address the
questions of reproducibility and diagnostic performance
of mpMRI in the setting of bladder ca (BC), in which
potential applications of this imaging technique have seen
constant growth in the past decades without a definitive
role having been identified.
The cohort the authors used in their study comprised
37 patients with MIBC and 37 with non-muscle-invasive BC
(NMIBC). They all underwent a VI-RADS-compliant mpMRI
protocol, including T2-weighted sequences, diffusion-
weighted imaging (DWI) sequences, and dynamic con-
trast-enhanced (DCE) imaging. Five genitourinary radiolo-
gists independently analyzed the target lesions identified
by a study coordinator and assigned a likelihood of bladder
muscle invasion primarily on the basis of the tumor
appearance on T2-weighted images and a final score
according to DWI and DCE images. In terms of interobserver
agreement, there was high reproducibility among the five
readers, with an intraclass correlation coefficient ofDOI of original article: https://doi.org/10.1016/j.eururo.2019.03.012.
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characteristic curve was 0.90, which confirms the great
potential of mpMRI as a diagnostic tool for BC.
Ueno et al. [1] shed light on contemporary mpMRI for
bladder applications by validating the recently proposed
reporting system. mpMRI assessment of BC is not new to
radiology: the first reports demonstrating its ability to
correctly stage local disease date back to the 1990s [3]. In
the past, further improvements in MRI techniques and
namely the implementation of functional techniques such
as DWI and DCE into the traditional T1- and T2-based
protocol, have legitimized its use in differentiating MIBC
fromNMIBC [4]. In this regard, the description of the “tumor
stalk” semiotics by Takeuchi et al. [5] can undoubtedly be
considered a milestone. More recently, two meta-analyses
[6,7] calculated pooled sensitivity of 87% and 92% and
specificity of 79% and 87%, respectively, in distinguishing
between MIBC and NMIBC, corroborating the maturity of
mpMRI for adoption in clinical practice.
However, according the European Association of Urology
guidelines [8], the diagnosis and local staging of BC rely on
cystoscopy and histological evaluation of bladder tissue.
Imaging techniques such as computed tomography andMRI
are mainly reserved for lymph node and distant disease
staging, with the important caveat that neither technique
can be used to assess the primary tumor stage. It is well
known that guidelines lag behind the best current clinicalPathology, Sapienza University of Rome, Viale Regina Elena 324, Rome
ma1.it (V. Panebianco).
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improvement in BC management is not getting the
attention it deserves. The current standard for diagnosis
and local staging of BC is TURBT, an invasive procedure that
carries a risk of bladder perforation and, perhaps more
importantly, a significant risk of understaging that might
delay radical treatment [9,10]. In addition, there is great
variability in the quality of TURBT and pathologists might
disagree on BC grading and staging. Thus, integration of
imaging in the local staging of BC is to be welcomed if it can
improve overall accuracy.
Despite the undeniable advances in mpMRI of the
bladder, there has been a lack of standardization in terms
of protocol and reporting. The aim of the promoters of the
VI-RADS was to bridge this gap, and the work by Ueno et al.
[1] comes at the perfect time. Their results suggest that
mpMRI of the bladder can be a valuable tool for men with
BC. Urologists should be confident with the information
provided by mpMRI as it can appropriately determine the
depth and range for excision sites, lowering the risk of
bladder perforation with a concomitant increase in
diagnostic accuracy. Furthermore, the proportion of false
negative examinations (ie, the number of MIBCs assigned to
the low-probability categories) is on the safe side, as they
found only four MIBCs out of 33 category 1 and 2 tumors.
These data are in accordance with a recent single-center
validation of VI-RADS [11], which also found a low
proportion of false negatives (5–10%, depending on the
reader) in a similar cohort.
So should we perform mpMRI before TURBT in all
patients with BC? It is likely that the road ahead for a new
paradigm that incorporates mpMRI into the initial workup
for these patients is still long, but there is no reason to slow
down. The evidence available at present is clearly insuffi-
cient to justify the routine use of mpMRI before performing
TURBT. Larger, multicentre and possibly randomized trials
are needed to demonstrate definitively the advantages of
mpMRI implementation. In addition, the presence of a
learning curve for radiologists must be taken into account:
both of the aforementioned studies have a “privileged”
setting involving dedicated radiologists at an academic
centre or a study coordinator who chose the target lesions,
which limits their applicability.
The time is favorable for standardizing and extending the
use of mpMRI of the bladder, and above all for making
urologists aware that they may have a new tool for accurate
diagnosis and staging of BC. Finally, there is no reason to
limit mpMRI to an adjunct tool before TURBT, as several
authors have suggested its use in assessing bladder tumorbefore and after immunotherapy prior to radical cystectomy
[12]. A new era for bladder imaging has already started, we
just need to keep pace.
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